ACRO Biomedical Co., Ltd. (6748) - Total Assets
Based on the latest financial reports, ACRO Biomedical Co., Ltd. (6748) holds total assets worth NT$607.52 Million TWD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ACRO Biomedical Co., Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how ACRO Biomedical Co., Ltd.'s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ACRO Biomedical Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
ACRO Biomedical Co., Ltd.'s total assets of NT$607.52 Million consist of 80.8% current assets and 19.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 29.3% |
| Accounts Receivable | NT$9.54 Million | 1.5% |
| Inventory | NT$10.70 Million | 1.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$6.33 Million | 1.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how ACRO Biomedical Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ACRO Biomedical Co., Ltd.'s current assets represent 80.8% of total assets in 2024, an increase from 60.5% in 2019.
- Cash Position: Cash and equivalents constituted 29.3% of total assets in 2024, down from 37.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 1.6% of total assets.
ACRO Biomedical Co., Ltd. Competitors by Total Assets
Key competitors of ACRO Biomedical Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
|
China | CN¥9.09 Billion |
ACRO Biomedical Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 28.89 | 39.89 | 27.68 |
| Quick Ratio | 28.20 | 39.23 | 26.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$464.73 Million | NT$548.10 Million | NT$338.16 Million |
ACRO Biomedical Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between ACRO Biomedical Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.23 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | -8.6% |
| Total Assets | NT$655.33 Million |
| Market Capitalization | $150.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values ACRO Biomedical Co., Ltd.'s assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ACRO Biomedical Co., Ltd.'s assets decreased by 8.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ACRO Biomedical Co., Ltd. (2019–2024)
The table below shows the annual total assets of ACRO Biomedical Co., Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$655.33 Million | -8.57% |
| 2023-12-31 | NT$716.74 Million | +79.85% |
| 2022-12-31 | NT$398.53 Million | +163.43% |
| 2021-12-31 | NT$151.28 Million | -25.63% |
| 2020-12-31 | NT$203.43 Million | +37.02% |
| 2019-12-31 | NT$148.46 Million | -- |
About ACRO Biomedical Co., Ltd.
ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials. The company offers products in the areas of wound care, orthopedics, dentistry, ophthalmology, cosmetic micro plastic surgery, beauty and eye care, and tissue engineering and regenerative medicines. The company was founded in 2014 and is based in Kaohsiung, Taiwan.